United Therapeutics Corporation· UTHR

🇺🇸 US · LargeSP400NASDAQ

Healthcare Biotechnology Website

Price: $494.63
Day: -0.53%
Mkt Cap: $21.00B
52W Range: $408.75 – $609.35
Volume: 1.47M
Beta: 0.56

5D Framework

Company Overview

Snapshot of fundamentals, performance, and 5D scores.

5D scores: Quality 3.6, Peers 4.0, Valuation 5.0, Analysts 3.3, Holdings 3.2 (out of 5)
Market: $494.63 a share, market cap $21.00B, +20.7% over 12 months
Company: Healthcare · Biotechnology, 1,400 employees, NASDAQ

Blog

Company Profile

Business fundamentals and company information

Business Description

United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.

Key Details

CEO

Martine A. Rothblatt

Employees

1,400

Headquarters

Silver Spring, MD, US

IPO Date

Jun 1999

Exchange

NASDAQ Global Select

Phone

301 608 9292

Healthcare · Biotechnology

SEC filings

10-KFeb 25, 2026 10-QAug 5, 2026 8-KSep 8, 2026

Price Performance

Recent price action and historical returns

Price Performance

$494.63

Historical Returns

Price performance over time

1 Day

-0.53%

5 Day

-0.50%

1 Month

-6.52%

3 Months

-7.82%

6 Months

-5.66%

YTD

+1.51%

1 Year

+20.68%

3 Years

+124.15%

5 Years

+147.22%

10 Years

+289.44%

Revenue Analysis

How the business makes money, by product and geography

2025 revenue · 6 products

Revenue to Profit Flow · 2025

How revenue flows through the P&L: Products → Total Revenue → COGS → Gross Profit → operating costs (R&D, SG&A) → Operating Income → Tax / Interest → Net Income.

Learn how to read flow diagrams

5D Framework

Five lenses on the stock. Click any card to dive deeper.

Quality

Business fundamentals

3.6/5

Strong

View Details

Peers

Competitive position

4.0/5

Strong

View Details

Valuation

Model-based valuation (vs. price)

5.0/5

Well below estimate

View Details

Analysts

Wall Street sentiment

3.3/5

Neutral

View Details

Holdings

Smart money flows

3.2/5

Neutral

View Details

How to read these dimensions

The five dimensions are independent lenses on a company, not a single combined score. Read them together rather than in isolation: where one dimension scores differently from the others is often the most useful place to focus your own research. Each score is built from rules and weights you can adjust, so treat them as a transparent starting point for your analysis, not a recommendation to buy or sell.